165 related articles for article (PubMed ID: 8491050)
21. Influence of 1 alpha-hydroxy vitamin D3 (0.25 micrograms/day) and calcium carbonate on patients with chronic renal failure at the predialytic stage.
Okada K; Nagura Y; Takahashi S; Hatano M
Nihon Jinzo Gakkai Shi; 1989 Jun; 31(6):657-60. PubMed ID: 2795995
[TBL] [Abstract][Full Text] [Related]
22. Intravenous alfacalcidol once weekly suppresses parathyroid hormone in hemodialysis patients.
Al-Hilali N; Al-Humoud H; Al-Helal B; Al-Azmi M; Al-Kandari NH; Johny KV
Ther Apher Dial; 2008 Apr; 12(2):137-42. PubMed ID: 18387162
[TBL] [Abstract][Full Text] [Related]
23. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
[TBL] [Abstract][Full Text] [Related]
24. Effect of one haemodialysis treatment on the plasma concentrations of intact parathyroid hormone and ionised calcium: usefulness of end-dialysis values in evaluating the suppressibility of hyperparathyroidism.
Pietilä K; Mustonen J; Mörsky P; Seppälä E; Pasternack A; Koivula T
Nephrol Dial Transplant; 1989; 4(2):115-8. PubMed ID: 2496352
[TBL] [Abstract][Full Text] [Related]
25. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis.
Toussaint ND; Polkinghorne KR; Kerr PG; Somerville CA; Agar JW
Hemodial Int; 2007 Apr; 11(2):217-24. PubMed ID: 17403174
[TBL] [Abstract][Full Text] [Related]
26. Acute effect of dialysate calcium concentration and intravenous vitamin D3 on the secretion of parathyroid hormone in hemodialysis patients.
Saha H; Pietilä K; Mustonen J; Pasternack A; Mörsky P
Clin Nephrol; 1992 Sep; 38(3):145-8. PubMed ID: 1395167
[TBL] [Abstract][Full Text] [Related]
27. Intravenous 1,25(OH)2D therapy increases the intact parathyroid hormone secretion set point in hemodialyzed patients.
Brossard JH; Roy L; Lepage R; Gascon-Barré M; D'Amour P
Miner Electrolyte Metab; 1997; 23(1):25-32. PubMed ID: 9058366
[TBL] [Abstract][Full Text] [Related]
28. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
29. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.
Mactier RA; Van Stone J; Cox A; Van Stone M; Twardowski Z
Clin Nephrol; 1987 Nov; 28(5):222-6. PubMed ID: 3427832
[TBL] [Abstract][Full Text] [Related]
30. Can low-calcium peritoneal dialysis solution safely replace the standard calcium solution in the majority of chronic peritoneal dialysis patients?
Buijsen CG; Struijk DG; Huijgen HJ; Boeschoten EW; Wilmink JM
Perit Dial Int; 1996; 16(5):497-504. PubMed ID: 8914179
[TBL] [Abstract][Full Text] [Related]
31. Alphacalcidol oral pulses are effective in secondary hyperparathyroidism prior to dialysis.
Koskimies O; Ala-Houhala M
Clin Nephrol; 1996 Jul; 46(1):70-1. PubMed ID: 8832157
[TBL] [Abstract][Full Text] [Related]
32. Low calcium dialysate and hyperparathyroidism.
Duncan R; Cochrane T; Bhalla C; Michael J; Richards NT; Adu D
Perit Dial Int; 1996; 16 Suppl 1():S499-502. PubMed ID: 8728256
[TBL] [Abstract][Full Text] [Related]
33. Treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis.
Okada K; Takahashi S; Nagura Y; Hatano M
Nihon Jinzo Gakkai Shi; 1989 Oct; 31(10):1085-9. PubMed ID: 2615019
[TBL] [Abstract][Full Text] [Related]
34. CAPD with low calcium dialysate and calcium carbonate: results of a 24-week study.
Honkanen E; Kala AR; Grönhagen-Riska C; Ikäheimo R
Adv Perit Dial; 1992; 8():356-61. PubMed ID: 1361822
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy.
Rapoport J; Mostoslavski M; Ben-David A; Knecht A; Blau A; Arad J; Zlotnik M; Chaimovitz C
Nephron; 1996; 72(2):150-4. PubMed ID: 8684518
[TBL] [Abstract][Full Text] [Related]
36. Treatment of secondary hyperparathyroidism in hemodialyzed patients with high-dose calcium carbonate without vitamin D3 supplements.
Teruel JL; Tenorio MT; Rodríguez JR; Marc n R; Orofino L; Rivera M; Ortuño J
Am J Nephrol; 1999; 19(3):428-32. PubMed ID: 10393383
[TBL] [Abstract][Full Text] [Related]
37. Parathyroid hormone during maintenance dialysis: influence of low calcium dialysate, plasma albumin and age.
Heaf JG; Løkkegård H
J Nephrol; 1998; 11(4):203-10. PubMed ID: 9702872
[TBL] [Abstract][Full Text] [Related]
38. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease.
Tarrass F; Yazidi A; Sif H; Zamd M; Benghanem MG; Ramdani B
Clin Nephrol; 2006 Jun; 65(6):415-8. PubMed ID: 16792136
[TBL] [Abstract][Full Text] [Related]
39. [Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis].
Séchet A; Abighanem O; Said S; Rasombololona M; Morinière P; Brazier M; Fournier A
Nephrologie; 1999; 20(4):209-12. PubMed ID: 10480153
[TBL] [Abstract][Full Text] [Related]
40. Calcium salts of keto-amino acids, a phosphate binder alternative for patients on CAPD.
Macia M; Coronel F; Navarro JF; Gallego E; Herrero JA; Méndez ML; Chahin J; García J
Clin Nephrol; 1997 Sep; 48(3):181-4. PubMed ID: 9342490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
